ZYME stock forecast, quote, news & analysis
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics... Show more
Zymeworks (ZYME) Stock Analysis: Royalty Milestones and the Theravance Deal Reshape the Growth Story
Key Takeaways
- ZYME shares have traded in a relatively narrow range recently, posting a modest gain of roughly 1.8% over the trailing 30-day window to about $27.
- Zymeworks completed its acquisition of Theravance Biopharma in September 2026, adding the marketed COPD therapy YUPELRI and immediate revenue and cash flow.
- The U.S. FDA's approval of Ziihera (zanidatamab-hrii) in first-line HER2-positive gastroesophageal adenocarcinoma unlocked a $250 million milestone from partner Jazz Pharmaceuticals.
- The company is transitioning from a clinical-stage developer into a royalty- and asset-driven business with a diversified revenue base.
- Near-term catalysts include additional global regulatory milestones, commercialization of Ziihera, and advancing antibody-drug conjugate (ADC) pipeline data.
Current Market Snapshot
Zymeworks Inc. (ZYME) shares have been range-bound in recent weeks, reflecting a period of consolidation following a series of transformative corporate and regulatory developments. Based on available trading data, the stock was near the $27 level in mid-October 2026, up only about 1.8% from its closing price roughly 30 days earlier, when shares traded near $26.57. The company's market capitalization stood at approximately $1.9 billion.
This muted short-term move stands in contrast to a longer-term uptrend, as the shares have risen substantially from their 52-week lows. The stability suggests investors are weighing the company's growing royalty streams and newly acquired commercial assets against the execution risks inherent in a biotechnology transition. Institutional ownership remains concentrated among healthcare-focused funds, underscoring the stock's appeal to specialized biotech investors.
Zymeworks (ZYME) Business Overview and Competitive Position
Zymeworks is a global biotechnology company that manages a portfolio of licensed healthcare assets while developing a pipeline of novel, multifunctional biotherapeutics for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. The company engineered and developed Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody built on its proprietary Azymetric technology, which is licensed to Jazz Pharmaceuticals (JAZZ) and BeOne Medicines for development and commercialization in different territories.
Zymeworks' competitive advantage lies in its integrated drug-development engine, which combines multispecific antibody platforms with ADC technology. This capability has been validated through strategic partnerships with several global pharmaceutical companies and underpins an internal pipeline that includes ZW191 (a folate receptor alpha-targeting ADC), ZW251 (a GPC3-targeting ADC), and a preclinical pan-RAS ADC platform. Investors follow the stock closely because of its potential milestone payments, tiered royalties, and emerging internal pipeline.
Recent Developments Driving ZYME
The most consequential recent event was the completion of Zymeworks' acquisition of Theravance Biopharma in late September 2026. The transaction adds YUPELRI (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist for maintenance treatment of COPD, which is expected to contribute immediately accretive revenue and roughly $60 million in annualized cash flow. The deal also brings additional royalty interests, milestone payments, and an early-stage immunology and inflammation portfolio.
Earlier, in August 2026, the U.S. FDA approved Ziihera, with and without tislelizumab plus chemotherapy, for the first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma. This second FDA approval for zanidatamab in under two years triggered a $250 million milestone payment to Zymeworks from Jazz and further validates the molecule's commercial potential.
Supporting shareholder returns, Zymeworks has continued executing a share repurchase program of up to $125 million. The company also secured a non-dilutive royalty-backed financing arrangement with Royalty Pharma (RPRX) to strengthen its balance sheet. These capital-allocation actions, combined with new clinical data for ZW191 showing encouraging response rates in platinum-resistant ovarian cancer, have reinforced investor interest.
Trending AI Robots
For traders seeking a data-driven approach to market opportunities, Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section. These bots vary in strategy, timeframe, and performance metrics, giving users a range of approaches to evaluate. The page provides a convenient starting point for exploring how algorithmic tools analyze stocks like ZYME and the broader market.
2026 Outlook and What Investors Should Watch
Looking ahead, investors will focus on Zymeworks' ability to convert its regulatory progress into recurring revenue. Key factors include the commercial launch trajectory of Ziihera by Jazz, potential regulatory milestones in China, Europe, and Japan, and the integration of the Theravance assets into the company's financial profile. Management has indicated the acquisition positions Zymeworks as a diversified, revenue-generating business and expects to receive additional milestone payments tied to Ziihera approvals.
Pipeline catalysts also remain important. Continued data from the Phase 1 study of ZW191, progress in the ZW251 program, and the advancement of the pan-RAS ADC platform could shape the company's longer-term valuation. Macroeconomic factors, including biotech-sector sentiment and interest-rate conditions, may also influence the stock. As with all clinical-stage and newly diversified biotechs, execution, regulatory, and commercialization risks remain, and investors should monitor these developments rather than rely on any single catalyst.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZYME in +10.08% Uptrend, growing for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZYME advanced for three days, in 251 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ZYME as a result. In 71 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ZYME just turned positive on October 20, 2026. Looking at past instances where ZYME's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
ZYME moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for ZYME crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
ZYME broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZYME entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.100) is normal, around the industry mean (2.988). P/E Ratio (-13.918) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company for cancer & autoimmune treatment
Industry Biotechnology